Life SciencesHelix & CDC Extend SARS-CoV-2 Genomic Sequencing & Surveillance CollaborationSeptember 20, 2022
Life SciencesAnuva Announces Series A Closure and Enters Into a Strategic Partnership With HelixAugust 29, 2022
Public HealthHelix SARS-CoV-2 Test with a Locker System Receives FDA Emergency Use Authorization (EUA)August 5, 2022
Helix PartnersMemorial Hermann and Helix Partner on a Population Genomics Initiative Aimed at Driving Precision Health Care for TexansJune 28, 2022
Helix PartnersStudy Shows Importance of Ensuring Participant and Provider Follow-up After a Genetic Screening ResultApril 27, 2022
Helix PartnersThermo Fisher Scientific, Helix and Rosalind to Support National Program to Accelerate SARS-CoV-2 Variant IdentificationMarch 23, 2022
Helix PartnersHealthPartners, Helix partner to help create DNA testing program that helps families better understand their genetic healthMarch 7, 2022
Helix PartnersHelix and Renown Health publish largest-ever genome-wide rare variant analysis on thousands of clinical phenotypes and over 70,000 exomesJanuary 29, 2022
Company NewsHelix Expands Leadership Team to Support Rapid Growth into New Segments of HealthcareJanuary 5, 2022
Helix PartnersHelix & CDC to Study the Role of Human Genetics in Vaccine EffectivenessJanuary 4, 2022
Helix PartnersHelix to Advance and Scale Viral Early Warning Efforts with Financial Support from The Rockefeller FoundationDecember 23, 2021
Helix PartnersHelix and Cue Health Collaborate to Provide Individuals with Access to their COVID-19 Variant Sequencing InformationNovember 28, 2021
Helix PartnersMUSC and Helix launch In Our DNA SC, first-of-its-kind population genomics program to drive preventive, precision health care for South CaroliniansSeptember 20, 2021
Company NewsHelix Announces $50 Million Series C Funding to Continue Acceleration into Clinical Population Genomics and COVID-19 Viral SurveillanceJune 3, 2021